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Abstract
Background: The high burden of healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) is partially
due to excessive antimicrobial use both in human and animal medicine worldwide. How can technology help to
overcome challenges in infection prevention and control (IPC) and to prevent HAI and emerging AMR?
Methods: In June 2017, 42 international experts convened in Geneva, Switzerland to discuss four potential domains of
technology in IPC and AMR: 1) role and potential contribution of microbiome research; 2) whole genome sequencing;
3) effectiveness and benefit of antimicrobial environmental surfaces; and 4) future research in hand hygiene.
Results: Research on the microbiome could expand understanding of antimicrobial use and also the role of probiotics
or even faecal transplantation for therapeutic purposes. Whole genome sequencing will provide new insights in modes
of transmission of infectious diseases. Although it is a powerful tool for public health epidemiology, some challenges
with interpretation and costs still need to be addressed. The effectiveness and cost-effectiveness of antimicrobially
coated or treated environmental high-touch surfaces requires further research before they can be recommended for
routine use. Hand hygiene implementation can be advanced, where technological enhancement of surveillance,
technique and compliance are coupled with reminders for healthcare professionals.
Conclusions: The four domains of technological innovation contribute to the prevention of HAI and AMR at different
levels. Microbiome research may offer innovative concepts for future prevention, whole genome sequencing could
detect new modes of transmission and become an additional tool for effective public health epidemiology,
antimicrobial surfaces might help to decrease the environment as source of transmission but continue to raise more
questions than answers, and technological innovation may have a role in improving surveillance approaches and
supporting best practice in hand hygiene.
Keywords: Technology, Infection prevention and control, Microbiome, Whole genome sequencing, Copper, Hand
hygiene, CDC, ECDC, WHO
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Background
A panel of 42 international experts with backgrounds in
infection prevention and control (IPC), microbiology, in-
fectious diseases, public health, psychology, medical tech-
nology, and social sciences, convened for two days at the
Geneva Think Tank on IPC and antimicrobial resistance
(AMR) in June 2017 under the auspices of the US Centers
for Disease Control and Prevention (CDC), the World
Health Organization (WHO), and the University of Gen-
eva Hospitals and Faculty of Medicine (HUG). The experts
were from both high- and low-and-middle-income coun-
tries, and from all five continents. The objectives were to
develop a vision on IPC and AMR and to agree on a road
map for research and public health activities. Three dimen-
sions on IPC and AMR were discussed: 1) implementation
of IPC and antimicrobial stewardship; 2) technology in IPC
and AMR; and 3) broadening the global IPC network. This
is the second in a series of three 2017 Geneva IPC-Think
Tank papers; it summarises the discussions about technol-
ogy in the prevention of healthcare-associated infections
(HAIs) and AMR.
Methods
Four domains of technological innovation for IPC and
AMR were assessed: 1) role and potential of microbiome
research; 2) potential of whole genome sequencing
(WGS); 3) effectiveness and cost-effectiveness of anti-
microbial surfaces; and 4) future research in hand hy-
giene surveillance and improvement. The domains were
selected as a consensus by CDC, WHO, and HUG. Each
domain was introduced with a short summary presenta-
tion by one of the experts, before they were allocated to
four focus groups. The discussions were guided by a
moderator, tape recorded, and documented by writers.
The experts were invited to express their personal views,
expectations and concerns in relation to using technol-
ogy in IPC and AMR. At the end of the four discussion
rounds a plenary session was organised, where abstracts
from the groups were summarized.
Results
The role of the microbiome
The populations of microbial species living on or in the
human body are known as the microbiota; the micro-
biome is the total of the genes of the microbiota. While
the total number of human cells and microbial cells is
similar, there are 50 times more bacterial genes than hu-
man genes in or on a human individual (106 versus 2 ×
104) [1]. The majority of the microbiota, and of the
microbiome, is found in the intestines. Research on the
microbiome as part of our immune system is rapidly
progressing but has not yet emerged into a mature tech-
nology in relation to IPC or AMR.
The use of antibiotics interferes with the balance of the
microbiota, which results in diseases such as Clostridoides
difficile infection (CDI), or can promote the selection of
multidrug-resistance microorganisms (MDROs) [2]. Im-
proved understanding on the impact of antimicrobials on
the microbiome could improve stewardship efforts. Probio-
tics and faecal transplantation are two examples of micro-
biota restoration -related interventions with potential for
prevention and treatment [3–5], respectively. Probiotics
can be preventive (e.g. in the prevention of necrotizing en-
terocolitis in preterm infants) but also have the potential to
be harmful (e.g. in causing probiotic species-related infec-
tion in immunocompromised patients). IPC professionals
may be concerned particularly with the latter, but micro-
biota-based intervention as a prevention strategy for AMR
is innovative with beneficial potential. Microbiome research
can help in directing researchers to ask the right questions
on benefits and risks of such interventions, and to design
clinical studies with new products. Faecal transplantation
is a different way of influencing the microbiota, and
has been successfully tested to treat recurrent CDI.
However, in terms of AMR, additional research is still
needed to understand the impact and best uses of
this strategy.
Whole genome sequencing
Whole genome sequencing is another rapidly growing
field of research within IPC and AMR, and reports using
this technology are growing in numbers. Organisations
such as the US CDC and the European Centre for Dis-
ease Prevention and Control (ECDC) promote the use of
WGS because of its many strengths such as detailed spe-
cies identification, detection of antimicrobial resistance
at the mechanism level, reproducibility, and objective
comparison of data. For example, in 2018, all Swiss uni-
versity hospitals are routinely using this technology to
identify clusters and epidemics on a local, national and
international scale. Combining information on species
and antimicrobial resistance using WGS would be a par-
ticularly interesting advance in the monitoring of AMR
on regional, national and international levels.
This technology is still growing and a number of chal-
lenges need to be addressed. At least today, phenotypic in-
formation is needed to inform genotypic interpretation,
and data interpretation will constantly change over time.
Although some countries are investing in national data-
base platforms, there is a lack of valid international refer-
ence platforms. Today, WGS still is a research tool –
although advancing rapidly – and as such, many re-
searchers use their own standards and references for data
interpretation. Epidemiological use of WGS on the other
hand would need valid standards and international librar-
ies, even if the latter grow and change over time.
Zingg et al. Antimicrobial Resistance and Infection Control            (2019) 8:83 Page 2 of 5
Costs are currently still high, but new, less expensive
kits are becoming available. However, for low-and-mid-
dle-income countries, these kits might still be too expen-
sive. Whole genome sequencing needs highly trained
people, particularly for data analysis and interpretation,
which adds to the costs of this technology. Open source
software makes interpretation easier and faster than in the
past, and software integrating epidemiology data with
those from WGS are getting on the market.
Antimicrobial surfaces
There is agreement that hospital cleaning is key for pa-
tient safety and that materials and design should facili-
tate cleanliness. Surfaces in hospital environments are
often contaminated with microorganisms, however, to
what extent this contamination contributes to MDRO
transmission is not yet clear [6, 7]. It is known that
cleaning practices are inconsistent, and that surfaces
re-contaminate rapidly after cleaning.
Antimicrobial surfaces are intended to keep bacterial
loads low, and thus reduce the risk of pathogen trans-
mission. The added value of antimicrobial surfaces to a
clean hospital environment is largely unknown, and
other technologies may contribute more to patient
safety. Ideally, antimicrobial surfaces would not need
maintenance, but exhibit permanent effectiveness. How-
ever, such a technology is not yet in sight. Copper ap-
pears to be effective in reducing bioburden, but is
expensive and may even be stolen from hospitals (there
is an illegal market for copper in some countries).
Low-and-middle-income countries do not have the re-
sources to buy copper or other even more sophisticated
surfaces. Furthermore, all marketed products today need
to be manually cleaned. Thus, cost-effectiveness has
been difficult to be demonstrated. A number of ques-
tions (rather than answers) were raised for antimicrobial
surfaces by the experts: which surfaces in a hospital
should be coated: high-touch surfaces (used by different
people) such as door handles, surfaces in the patient
zone including textiles, toilets and showers, or any sur-
face in a patient room? Could there be resistance to sur-
face antimicrobials? Maybe, surfaces and equipment that
are carefully designed for easy cleaning would be more
effective and cost effective in the end.
Hand hygiene
Hand hygiene is the most widely promoted single inter-
vention for the prevention of HAI and transmission of
MDROs. Direct hand hygiene observation is considered
the best method to assess compliance, but, among key on-
going challenges with hand hygiene improvement, the
Hawthorne effect limits its validity [8]. There may be bet-
ter methods of measurement and feedback than direct
hand hygiene observation: there has been an explosion of
efforts to incorporate technology into hand hygiene meas-
urement. For example, a study using video surveillance
did highlight some success [9], while surveillance using
handrub counters showed effectiveness only after imple-
menting a positive deviance strategy [10].
Non-alcohol-based hand cleansing agents (with spori-
cidal activity) were considered to improve compliance and
act longer (particularly relevant for surgery), but no such
product is available for daily routine use at the frontline.
The experts perceived automated surveillance positively.
They decided that more research should be invested there,
with a view to providing more credible data than is cur-
rently obtained in many settings. The use of new
un-obtrusive surveillance technologies would be preferable,
even at the cost of accuracy. However, is such technology
affordable? Compared to the time needed for direct hand
hygiene observation, automated surveillance might be
cost-effective and would give IPC professionals time to
do other tasks. An emerging question is how new techno-
logical innovation could guide healthcare workers to per-
form hand hygiene at the right moment. Colour changing
products or electronic reminders were proposed as imagin-
able, forward-looking strategies. The ideal hand hygiene
agent would have to be fast acting, long-lasting,
quick-drying, and skin-friendly with a wide range of effect-
iveness (also towards spores and non-enveloped viruses).
Longer-lasting agents would be good, but more important
than duration is effectiveness. In addition to effectiveness,
other aspects such as price, local production, and ecological
properties (waste) must be considered for future products.
Appropriate exposure time, application technique and opti-
mal number and placement of handrub dispensers are add-
itional research questions.
Discussion
The IPC community has focussed on best practices for
the prevention of HAI and AMR in recent years, includ-
ing aspects related to implementation and behaviour
change. However, at the same time new technologies are
being evaluated or are becoming more broadly available.
The microbiota has a number of functions in nutrition,
metabolism, and maturation of the immune system, and
thus, research on this topic going beyond probiotics and
faecal transplantation, including diagnostics, should
draw the attention of the IPC community. The benefits
in the prevention of HAI and AMR need to be more
fully established. Whole genome sequencing is a promis-
ing technology and a powerful tool for future epidemi-
ology in both IPC and AMR. Public health interests are
different from research interests, and using WGS for
public health purposes requires coordinated standards
and infrastructure. International organisations should
work together with national public health bodies, experts
and researchers of the IPC community to foster outputs
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of interest for public health such as quality assurance of
WGS, standardised methodologies, and international li-
braries. Antimicrobial surfaces are unlikely to play an
important role in the short term given their expense and
lack of efficacy data supporting wide adoption. There is
agreement that the evidence for measurable effectiveness
is poor and thus, broad recommendations of antimicro-
bial surfaces cannot be justified at this time. Hand hy-
giene research now needs to be taken to the next level;
in particular, accurate surveillance, appropriate tech-
nique, required amount of handrub, and automatic re-
minders for healthcare professionals would be of
interest. However, given that hand hygiene is and re-
mains driven by the behaviour of healthcare profes-
sionals, all future aspects taking into account new
technology should be considered within a multimodal
improvement strategy.
The time available to discuss technology was short,
limiting the aim to obtain consensus on a road map for
all four topics. The role of the microbiota in IPC was a
new concept, and except from using probiotics and ap-
plying faecal transplantation to treat CDI and to address
AMR, there was limited time to discuss this concept in a
wider range (e.g. the role of the hospital microbiota). In
the discussion on WGS, some experts expressed con-
cerns about this technology being already sufficiently ad-
vanced and reproducible to serve as a gold standard.
Thus, both microbiota and WGS will be the two topics
to be discussed in the next Geneva think tank.
Conclusion
The four domains of technological innovation contribute
to the prevention of HAI and AMR at different levels.
Microbiome research may offer innovative concepts for
future prevention, whole genome sequencing could detect
new modes of transmission and become an additional tool
for effective public health epidemiology, antimicrobial sur-
faces might help to decrease the environment as source of
transmission but continue to raise more questions than
answers, and technological innovation may have a role in
improving surveillance approaches and supporting best
practice in hand hygiene.
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